These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20210018)

  • 1. [Prognostic significance of cell proliferation, microvascular density and androgen receptor level in prostatic adenocarcinoma].
    Lefterov SI; Gorelov SI; Krivolapov IuA
    Vopr Onkol; 2009; 55(6):740-5. PubMed ID: 20210018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer.
    Ishida E; Nakamura M; Shimada K; Tasaki M; Konishi N
    Pathobiology; 2009; 76(1):30-8. PubMed ID: 19188748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipofuscin pigment can be used as a prognostic marker in prostatic adenocarcinoma.
    Mahmoodi M; Zhang S; Salim S; Hou JS; Garcia FU
    Ann Diagn Pathol; 2006 Oct; 10(5):257-62. PubMed ID: 16979516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME; Goddard L; Smith C; Nicholson RI
    Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer.
    Aaltomaa S; Lipponen P; Vesalainen S; Ala-Opas M; Eskelinen M; Syrjänen K
    Eur Urol; 1997; 32(4):410-5. PubMed ID: 9412797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.
    Tezval H; Jurk S; Atschekzei F; Serth J; Kuczyk MA; Merseburger AS
    Prostate; 2009 Mar; 69(4):443-8. PubMed ID: 19058138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
    Shimizu Y; Segawa T; Inoue T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Terada N; Kobayashi T; Kinoshita H; Kamoto T; Nakamura E; Ogawa O
    BJU Int; 2007 Sep; 100(3):685-90. PubMed ID: 17542985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor expression and angiogenesis in human prostate carcinoma.
    Abdulkadir SA; Carvalhal GF; Kaleem Z; Kisiel W; Humphrey PA; Catalona WJ; Milbrandt J
    Hum Pathol; 2000 Apr; 31(4):443-7. PubMed ID: 10821491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
    Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
    J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31.
    de la Taille A; Katz AE; Bagiella E; Buttyan R; Sharir S; Olsson CA; Burchardt T; Ennis RD; Rubin MA
    Am J Clin Pathol; 2000 Apr; 113(4):555-62. PubMed ID: 10761458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
    Stefanou D; Batistatou A; Kamina S; Arkoumani E; Papachristou DJ; Agnantis NJ
    In Vivo; 2004; 18(2):155-60. PubMed ID: 15113042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
    Djordjevic G; Mozetic V; Mozetic DV; Licul V; Ilijas KM; Mustac E; Oguic R; Fuckar Z; Jonjic N
    Pathol Res Pract; 2007; 203(2):99-106. PubMed ID: 17270362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.